BOULDER, Colo.–(BUSINESS WIRE)–BioMed Realty, the largest private owner and operator of real estate for the life science, technology and innovation industries, announced that CordenPharma Colorado, a leading peptide drug substance Contract Development and Manufacturing Organization (CDMO), has leased 64,000 square feet at Flatiron Park’s 5505 Central – Boulder’s first purpose-built speculative lab building – near the existing CordenPharma Colorado facility. Flatiron Park is BioMed Realty’s pr
BioMed Realty and CordenPharma Colorado Team Up for Expansion of Peptide Development Lab in New LEED® Gold-Certified Facility at Flatiron Park in Boulder
